The Study of Antiviral Drugs' Activity Against The Causative Agent of Zika Fever in Cell Culture
Abstract
Zika virus (ZIKV) is a representative of the viruses of the genus Flavivirus in the family Flaviviridae, it belongs to the zoonotic arbovirus infections transmitted by mosquitoes of the genus Aedes. In humans, this flavivirus causes a disease known as zika fever, etymologically related to yellow fever, dengue, West Nile and Chikungunya viruses. There is no specific treatment for zika fever, just as there is no vaccine or preventive measures available to date. A comparative analysis of the effectiveness of chemotherapy medications, interferon inducers and two classes of interferon α-, β-, and γ- showed that interferon drugs effectively inhibit the reproduction of Zika virus in Vero cell culture in a wide range of concentrations. Chemotherapy medications Triazavirin®, Virazole®, Zovirax®, Cytarabine®, and Ingavirin® did not affect the reproduction of Zika virus strain MR 766V in Vero cell culture. The size of negative Zika virus colonies was significantly reduced in the presence of Virazole® and Ribavirin® at a concentration of 100 μg/ml. zika virus, Triazavirin®, Ribavirin®, Ingavirin®, Reaferon-EU®, Rebif(fila)®, antiviral efficacy
About the Authors
S. Ya. Loginova
48th Central Scientific Research Institute of the Ministry of Defence of the Russian Federation
Russian Federation
Russian Federation
V. N. Shchukina
48th Central Scientific Research Institute of the Ministry of Defence of the Russian Federation
Russian Federation
Russian Federation
G. V. Borisevich
48th Central Scientific Research Institute of the Ministry of Defence of the Russian Federation
Russian Federation
Russian Federation
I. V. Surovyatkina
48th Central Scientific Research Institute of the Ministry of Defence of the Russian Federation
Russian Federation
Russian Federation
S. V. Borisevich
48th Central Scientific Research Institute of the Ministry of Defence of the Russian Federation
Russian Federation
Russian Federation
References
1. Mumtaz N., van Kampen J.J., Reusken СБ., Boucher C.A., Koopmans M.P. Zika Virus: Where Is the Treatment? Curr Treat Options Infect Dis 2016; 8: 208-211. doi: 10.1128/CMR.00072-15.
2. Frumence E. Roche M., Krejbich-Trotot P. The South Pacific epidemic strain of Zika virus replicates efficiently in human epithelial A549 cells leading to IFN-? production and apoptosis induction. Virology 2016; 493: 217-226. doi: 10.1016/j.virol.2016.03.006.
3. Shao W., Espenshade P.J. Expanding roles for SREBP in metabolism. Cell. Metab 2012; 16: 414-419. doi: 10.1016/j.cmet.2012.09.002.
4. Soto-Acosta R. Bautista-Carbajal P., Syed G. H., SiddiquiA., Del Angel R. M. Nordihydroguaiaretic acid (NDGA) inhibits replication and viral morphogenesis of dengue virus. Antiviral Res. 2014; 109: 132—140. doi: 10.1016/j.antiviral.2014.07.002.
5. Syed G. K, SiddiquiA. Effects of hypolipidemic agent nordihydroguaiaretic acid on lipid droplets and hepatitis С virus. Hepatology. 2011; 54: 1936-1946. doi: 10.1002/hep.24619.
6. NourA. M. Li Y., Wolenski J., Modis Y. Viral membrane fusion and nucleocapsid delivery into the cytoplasm are distinct events in some flaviviruses. PLoS Pathog 2013; 9: el003585. doi.org/10.1371/joumal.ppat.1003585.
7. Potlara J. J, Laster S. М., Petty I. Т. Inhibition of poxvirus growth by Terameprocol, a methylated derivative of nordihydroguaiaretic acid. Antiviral Res 2010; 88: 287-295. doi: 10.1016/j.antiviral.2010.09.017.
8. Chen Q. Nordihydroguaiaretic acid analogues: their chemical synthesis and biological activities. Curr Top Med Chem 2009; 9: 1636—1659.
9. Grossman S. A. Ye X., Peereboom D., Rosen/eld M. R., Mikkelsen Т., Supko J. G, Desideri S. Phase I study of terameprocol in patients with recurrent high-grade glioma. Neuro Oncol 2012; 14: 511—517. doi: 10.1093/neuonc/nor230.
10. Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ. М.: Минздрав РФ, 2013; 942с. / Rukovodstvo ро provedeniju doklinicheskih issledovanij lekarstvennyh sredstv. chast' 2. M.: Minzdrav R.F., 2005. [In Russian]
11. Eyer L., Nencka ., Huvarovd I., Palus M., Joao Alves M., Gould E.A., De Clercq E., Riizek D. Nucleoside Inhibitors of Zika Virus. J Infect Dis. 2016; Sep 1; 214 (5): 707-711. doi: 10.1093/infdis/jiw226. Epub 2016 May 27.
12. Boding C, Kuhn R.J. Novel approaches to flavivirus drug discovery. Expert. Opin Drug Discov2012; 7 (5): 417-428. doi: 10.1517/1760441. 2012.673579. Epub 2012 Mar 22.
Review
For citations:
Loginova S.Ya., Shchukina V.N., Borisevich G.V., Surovyatkina I.V., Borisevich S.V. The Study of Antiviral Drugs' Activity Against The Causative Agent of Zika Fever in Cell Culture. Antibiot Khimioter = Antibiotics and Chemotherapy. 2018;63(9-10):14-18. (In Russ.)
Views:
415
Email this article 